Medtronic Plc

Medtronic develops and manufactures medical devices for chronic disease management including cardiac pacemakers, insulin pumps, spinal implants, and surgical tools. The company generates revenue from device sales to hospitals and recurring revenue from consumables like neurostimulator leads and sensor replacements. Major therapy areas include cardiovascular devices, diabetes management technology, neurological treatments, and minimally invasive surgical systems. Medtronic sells through direct representatives and distributor networks globally.

Medtronic offers exposure to aging demographics driving demand for cardiac and spinal procedures. The company provides stable cash flows from installed base consumables and maintains global market leadership in several device categories. Challenges include pricing pressure from hospital group purchasing organizations, innovation cycles creating product obsolescence risk, and recalls affecting specific product lines. The stock typically trades at modest valuations reflecting mature market growth.

Abbott Laboratories competes in cardiac devices, diabetes monitoring, and vascular products. Boston Scientific challenges in cardiovascular interventions and neuromodulation. Johnson & Johnson competes through Biosense Webster in cardiac ablation. Stryker contests in surgical technologies and neurovascular devices, while Dexcom competes specifically in continuous glucose monitoring systems.

Medtronic has increased dividends consecutively for over 40 years, achieving dividend king status. The company maintains a moderate payout ratio allowing investment in R&D and clinical trials for device approvals. Dividend growth has continued through the Ireland domicile transition and major acquisitions.

MDT last closed at $80.13, down 0.62% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $73.31 and a high of $106.33. The current price represents 21% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 37 analysts covering MDT, the consensus rating is Buy — 21 rate it a buy, 15 hold, and 1 sell. The average price target sits at $192.46, implying 140% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Medtronic Plc generated $36.24B in revenue during fiscal year 2026, with $4.78B reaching the bottom line as net income. The net profit margin of 13.2% is solid for its sector.

MDT trades at a P/E ratio of 21.21 on trailing earnings of $3.73 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -16.66% (6M), -6.79% (1Y), -16.57% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether MDT is outperforming or lagging the broader market.